Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 441 | 76 | 358 |
| Samples | 411 | 74 | 330 |
| Peptides | 292 | 47 | 258 |
Function
FMO3 · Flavin containing dimethylaniline monoxygenase 3
Flavin-containing monooxygenases (FMO) are an important class of drug-metabolizing enzymes that catalyze the NADPH-dependent oxygenation of various nitrogen-,sulfur-, and phosphorous-containing xenobiotics such as therapeutic drugs, dietary compounds, pesticides, and other foreign compounds. The human FMO gene family is composed of 5 genes and multiple pseudogenes. FMO members have distinct developmental- and tissue-specific expression patterns. The expression of this FMO3 gene, the major FMO expressed in adult liver, can vary up to 20-fold between individuals. This inter-individual variation in FMO3 expression levels is likely to have significant effects on the rate at which xenobiotics are metabolised and, therefore, is of considerable interest to the pharmaceutical industry. This transmembrane protein localizes to the endoplasmic reticulum of many tissues. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms. Mutations in this gene cause the disorder trimethylaminuria (TMAu) which is characterized by the accumulation and excretion of unmetabolized trimethylamine and a distinctive body odor. In healthy individuals, trimethylamine is primarily converted to the non odorous trimethylamine N-oxide.[provided by RefSeq, Jan 2016].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000367755 | P31513 | 441 | 292 |
Gene Properties
Recurrent Mutations
All 292 amino-acid changes on canonical ENST00000367755 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FMO3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FMO3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 4/210 2% | 101/1899 5% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Endometrial Carcinoma | 3/42 7% | 14/612 2% |
| Rhabdomyosarcoma | 1/33 3% | 4/171 2% |
| Bladder Carcinoma | 1/58 2% | 22/956 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 16/304 5% | 20/1390 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 13/810 2% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Colorectal Carcinoma | 3/143 2% | 38/3239 1% |
| Gastric Carcinoma | 4/74 5% | 18/1809 1% |
| Osteosarcoma | 1/45 2% | 1/166 1% |
| Other Solid Cancers | 2/94 2% | 13/1515 1% |
| Ovarian Carcinoma | 6/109 6% | 3/998 0% |
| Other Sarcomas | 0/69 0% | 6/699 1% |
| Cervical Carcinoma | 1/35 3% | 2/422 0% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Neuroendocrine Tumour | 3/154 2% | 1/577 0% |
| Head and Neck Carcinoma | 0/85 0% | 9/1574 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Biliary Tract Carcinoma | 0/54 0% | 5/950 1% |
| Neuroblastoma | 5/87 6% | 2/1331 0% |
| Non-Cancerous | 1/104 1% | 3/830 0% |
| B-Cell Non-Hodgkins Lymphoma | 4/88 5% | 7/2534 0% |
| Breast Carcinoma | 4/144 3% | 9/3264 0% |
| Hepatocellular Carcinoma | 0/46 0% | 7/2210 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 8/2550 0% |
Mutation Distribution
Where FMO3 is mutated · all tissues, split by cell line vs tissue
How many mutations in FMO3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 441 mutations in FMO3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|